Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDORA-LOW adalimumab concentration-targeted dose reduction trial in rheumatoid arthritis
NL-OMON55177Not yet recruiting
- Sponsor
- Reade
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, single-blind trial of adalimumab in rheumatoid arthritis (RA), sponsored by Reade. Primary endpoint: Difference in mean time weighted DAS28-CRP between week 0 and 24. Planned start May 2019; status: not yet recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON55177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55177.